Publications:

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels.

Molecular Metabolism

Gaillard, Carole Fruchart CF; Ben Djoudi Ouadda, Ali A; Ciccone, Lidia L; Girard, Emmanuelle E; Mikaeeli, Sepideh S; Evagelidis, Alexandra A; Le Dévéhat, Maïlys M; Susan-Resiga, Delia D; Lajeunesse, Evelyne Cassar EC; Nozach, Hervé H; Pereira Ramos, Oscar Henrique OH; Thureau, Aurélien A; Legrand, Pierre P; Prat, Annik A; Dive, Vincent V; Seidah, Nabil G NG

Publication Date: 2022-12-22

Variant appearance in text: PCSK9: D480N

PubMed Link: 36566984

Variant Present in the following documents:

• Main text
• main.pdf
• mmc1.pdf

View BVdb publication page

Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.

The Journal Of Biological Chemistry

Benjannet, Suzanne S; Hamelin, Josée J; Chrétien, Michel M; Seidah, Nabil G NG

Publication Date: 2012-09-28

Variant appearance in text: PCSK9: D480N

PubMed Link: 22875854

Variant Present in the following documents:

• Main text

View BVdb publication page